Organon & Co | OGN - Current Liabilities


Organon & Co reported $2.68B in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Celltrion KRW 4.01T 343.96B Sep/2025
Cspc Pharmaceutical CNY 10.11B 478.47M Jun/2025
Dianthus Therapeutics USD 23.86M 3.76M Sep/2025
Divis Laboratories Ltd INR 17.28B 2.76B Sep/2025
Gilead Sciences USD 12.3B 1.11B Sep/2025
Glaxosmithkline GBP 28.68B 8.3B Sep/2025
Kangmei Pharma CNY 5.81B 57.93M Sep/2025
Knight Therapeutics CAD 118.15M 12.32M Sep/2024
Laboratorios Farma EUR 199.84M 121.75M Dec/2023
Malin Corporation EUR 1000K 500K Dec/2024
Medical Developments International AUD 7.82M 1.45M Jun/2025
Merck USD 28.63B 2.59B Sep/2025
Neuren Pharmaceuticals AUD 7.92M 37.84M Jun/2025
Novartis USD 32B 286M Sep/2025
Organigram Holdings CAD 126.16M 18.88M Sep/2025
Organon & Co USD 2.68B 117M Sep/2025
Pharma Mar EUR 88.93M 1.15M Sep/2025
Qiagen NV USD 973.4M 154.91M Sep/2025
Sartorius EUR 1.81B 254.3M Sep/2025
Sino Biopharmaceutical CNY 24.85B 5.29B Jun/2025
Tilray USD 280.3M 18.13M Mar/2025